AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04823052
Drug: Sulindac (HLX-0201), dose strength 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (HLX-0201) Capsule
Trial: NCT04823052
Drug: Sulindac (HLX-0201), dose strength 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (HLX-0201) Capsule
Trial: NCT04823052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule
Trial: NCT03988439
Drug: IDP-118 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT04768478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
Trial: NCT05623605
Drug: Indian costus mouth wash
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
Trial: NCT05736887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in 600mg tablets
Trial: NCT04983238
Drug: BYON5667 & SYD985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular administration: BYON5667, Intravenous administration: SYD985
Trial: NCT04983238
Drug: Placebo & SYD985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular administration: Placebo, Intravenous administration: SYD985
Trial: NCT05677126
Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralement without Manganese
Trial: NCT04846868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06682975
Drug: ZP9830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
Trial: NCT06682975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
Trial: NCT06690229
Drug: glass ionomer cement
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cement used for crown cementation
Trial: NCT06695208
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biodentine used in socket preservation
Trial: NCT06694324
Drug: Liposomal Doxorubicin (Doxil)
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2, d1, IV
Trial: NCT06690476
Drug: Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
Trial: NCT06691425
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
Trial: NCT06398054
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg tablet
Trial: NCT06398054
Drug: Hyoscine N-Butil Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-Butil Bromide 10 mg two tablets
Trial: NCT06538012
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT06398054
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets
Trial: NCT06274047
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06496100
Drug: Placebo (calcined magnesia)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Trial: NCT05385523
Drug: dexamedatomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
Trial: NCT06636422
Drug: Motherwort injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Trial: NCT06421454
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pressure Ulcer will be treated with a melatonin cream daily
Trial: NCT06421454
Drug: Hydrogel
RxNorm normalized name: HYDROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure ulcer will be treated with hydrogel daily as a comparator
Trial: NCT04739215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Placebo capsule daily oral
Trial: NCT06637384
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
Trial: NCT06357377
Drug: NEO100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.
Trial: NCT06643780
Drug: Zolendronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Trial: NCT05804084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar capsule manufactured to match encapsulated Acetazolamide
Trial: NCT06475495
Drug: KYV101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Trial: NCT06304896
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
Trial: NCT06304896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
Trial: NCT05812300
Drug: Freshly manufactured 35 kDa hyaluronan fragment
RxNorm normalized name: PALMITOYL FRAGMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
Trial: NCT06054815
Drug: DA-1241 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of Administration: Oral, with subjects in a fasting state
Trial: NCT06541249
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
Trial: NCT05025605
Drug: BXCL501 80 Micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual film containing 80 Micrograms BXCL501
Trial: NCT05025605
Drug: Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Sublingual Placebo film
Trial: NCT05025605
Drug: BXCL501 120 Micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual film containing 120 Micrograms BXCL501
Trial: NCT05025605
Drug: BXCL501 60 Micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual film containing 60 Micrograms BXCL501 Europe Only
Trial: NCT05730478
Drug: Glaucoma therapy
RxNorm normalized name: Sympathomimetics in glaucoma therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASOCT and UBM parameters Comparison
Trial: NCT05730478
Drug: Glaucoma therapy
RxNorm normalized name: Sympathomimetics in glaucoma therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison
Trial: NCT05486065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
Trial: NCT06380907
Drug: ZL-1102 1% w/w gel BID for 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZL-1102~1% w/w gel BID for 16 weeks
Trial: NCT06380907
Drug: ZL-1102 3% w/w gel BID for 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZL-1102 3% w/w gel BID for 16 weeks
Trial: NCT06380907
Drug: ZL-1102 3% w/w gel QD for 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZL-1102 3% w/w gel QD for 16 weeks
Trial: NCT06380907
Drug: Placebo ZL-1102 0% w/w gel BID for 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 0% w/w gel BID for 16 weeks
Trial: NCT06380907
Drug: Placebo ZL-1102 0% w/w gel QD for 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 0% w/w gel QD for 16 weeks
Trial: NCT05178654
Drug: [14C]PF-07321332
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
Trial: NCT06255626
Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
Trial: NCT05376969
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 Tablets
Trial: NCT05120297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
Trial: NCT05175001
Drug: Diprospan
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
Trial: NCT05388825
Drug: TPN171H 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Trial: NCT05388825
Drug: TPN171H 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Trial: NCT05388825
Drug: TPN171H 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Trial: NCT05388825
Drug: Placebo 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Trial: NCT05388825
Drug: Placebo 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Trial: NCT06044623
Drug: CDK 4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either Palbociclib, Ribociclib or Abemaciclib
Trial: NCT06044623
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Trial: NCT04907539
Drug: RXC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules.
Trial: NCT06640582
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Trial: NCT06642961
Drug: GR1802 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR1802 will be administered SC.
Trial: NCT05870111
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
Trial: NCT05059626
Drug: simvastatin 10mg
RxNorm normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastation acts as a systemic LOX inhibitor.
Trial: NCT05526157
Drug: Non-steroidal mineral corticoid receptor antagonists (nsMRA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective analysis using secondary data collection from various sources
Trial: NCT04989218
Drug: Novel combination of chemotherapy and immunotherapy
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
Trial: NCT04725188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV infusion Q3W up to approximately 2 years
Trial: NCT06148948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1584862
Trial: NCT05557292
Drug: RMC-5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06169579
Drug: ND-003 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
Trial: NCT06169579
Drug: ND-003 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ND-003 tablets will be administered orally over continuous 28-days cycles.
Trial: NCT06402136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04918771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration - not with food. Placebo using Raphamin scheme.
Trial: NCT04551053
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered QD orally
Trial: NCT05059522
Drug: Lorlatanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05059522
Drug: CMP 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT (intratumoral) or SC (subcutaneous)
Trial: NCT05059522
Drug: PF04518600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05177328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline and glycerol
Trial: NCT06678581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid Oral Tablet
Trial: NCT06687421
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
Trial: NCT06686472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Trial: NCT06694740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Trial: NCT06693973
Drug: AcNK-Sup003 cell injection solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
Trial: NCT06359626
Drug: YHP2205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: YHP2205
Trial: NCT06359626
Drug: YHR2401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator: YHR2401
Trial: NCT04818177
Drug: Institutional standard intravenous immune globulin treatment
RxNorm normalized name: GLOBULIN,IMMUNE (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
Trial: NCT04744831
Drug: DS-8201a 5.4 mg/kg Q3W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
Trial: NCT04744831
Drug: DS-8201a 6.4 mg/kg Q3W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
Trial: NCT05063136
Drug: Capecitabine+endocrine therapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
Trial: NCT05063136
Drug: Placebo+endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
Trial: NCT05654181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching active drug administered orally
Trial: NCT06375564
Drug: 177Lu-AB-3PRGD2 radioligand therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Trial: NCT05913180
Drug: Ascorbic Acid 1000 MG
RxNorm normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
Trial: NCT05913180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily starting day of elective gynecological surgery for 10 days
Trial: NCT05502900
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
Trial: NCT04839926
Drug: 0.5mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT04839926
Drug: 1.5mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT04839926
Drug: 4.5mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT04839926
Drug: 10mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT04839926
Drug: 18mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT04839926
Drug: 24mg CY150112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral CY150112 while fasting on day 1.
Trial: NCT06160778
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Trial: NCT06160778
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.